Cyclerion Therapeutics files to offer 6.1M shares of common stock for holders 16:2808/0708/07/20
Cyclerion Therapeutics reports Q2 revenue $0.7M vs. $1.6M last year » 09:2708/0308/03/20
Net loss was…
Net loss was approximately $20M for the second quarter of 2020, as compared to $32M for the second quarter of 2019. "We are looking forward to upcoming top line results from both our translational pharmacology study for IW-6463, the first brain-penetrant sGC stimulator to enter clinical development, and our STRONG olinciguat Phase 2 study for sickle cell disease. Both programs have the potential to provide a fundamentally new approach for patients with limited therapeutic options today", said Peter Hecht, Ph.D., Chief Executive Officer of Cyclerion.
|Over a week ago|
Cyclerion Therapeutics files $150M mixed securities shelf 17:1507/2407/24/20
Cyclerion Therapeutics announces presentation on biomarker data » 07:0307/1707/17/20
Cyclerion Therapeutics announced that Christopher Winrow, Ph.D., Senior Director, Neuroscience Development Program Lead, presented on "Leveraging Biomarker Data & Preclinical Models to Guide the Design of Clinical Studies" at the Annual Biomarkers in Alzheimer's Disease Summit that was held virtually on July 15, 2020. The presentation detailed the application of translational biomarkers to guide clinical activities for IW-6463, the Company's therapeutic candidate for CNS diseases. In preclinical studies, IW-6463 has demonstrated beneficial effects across four domains relevant to neurodegenerative diseases: cerebral blood flow, cellular bioenergetics, neuro-inflammation, and neuronal function. Cyclerion plans to develop IW-6463 in individuals with Alzheimer's disease with vascular pathology, as well as in MELAS, a genetically defined orphan disease. The Company is evaluating cerebrospinal fluid and plasma biomarkers and various imaging approaches to define optimal clinical endpoints.
Cyclerion Therapeutics to host conference call » 07:5507/0907/09/20
Management holds a…
Cyclerion Therapeutics to host conference call » 04:5507/0907/09/20
Management holds a…
|Over a month ago|
Cyclerion Therapeutics to host conference call » 17:0507/0207/02/20
Management holds a…
|Over a quarter ago|
Cyclerion closes enrollment on two ongoing clinical studies » 08:4404/1004/10/20
Cyclerion Therapeutics announced that it recently closed enrollment for both of its ongoing clinical studies. The company said, "We are looking forward to a catalyst-rich period in the coming months with top line results from both our translational pharmacology study for IW-6463, our brain-penetrant sGC stimulator designed to treat neurodegenerative diseases, and our olinciguat Phase 2 study for sickle cell disease. We also continue discussions on the out-licensing of praliciguat, a potential best-in-class therapeutic candidate for cardio-metabolic diseases. Recent published outcomes data from other groups provide compelling new support for the use of the sGC stimulator class in treating cardiometabolic diseases." It added, "The Company is tightly managing its spending. As of March 31, 2020, Cyclerion's preliminary unaudited cash, cash equivalents and restricted cash balance was approximately $72 million. Cyclerion anticipates that this cash will fund its operations into Q2 2021, excluding net cash flows from potential business development activities...The Company cannot give any assurances as to the potential impact of the pandemic on its operations, clinical trials, corporate development discussions and other activities. Cyclerion is working closely with its clinical trial sites and investigators to deliver its ongoing and planned trials in a manner consistent with the safety of study participants and healthcare professionals. Cyclerion does not anticipate any drug product disruption for its clinical trials and is taking steps to mitigate any disruptions of clinical supply materials to trial participants."
Cyclerion Therapeutics downgraded to Hold from Buy at Spin-Off Research » 10:0402/2602/26/20
Spin-Off Research downgraded Cyclerion Therapeutics to Hold from Buy with a $5 price target.
Ten new option listings and two option delistings on January 23rd » 08:3001/2301/23/20
AKRO, AQST, CYCN, ITRN, OBSV, PHAS, PHAT, STOK, XP, MDR, TOO
New option listings for…
New option listings for January 23rd include Akero Therapeutics Inc (AKRO), Aquestive Therapeutics Inc (AQST), Cyclerion Therapeutics Inc (CYCN), Ituran (ITRN), McDermott International Inc (MDRIQ), ObsEva (OBSV), PhaseBio Pharmaceuticals Inc (PHAS), Phathom Pharmaceuticals Inc (PHAT), Stoke Therapeutics Inc (STOK), and XP Inc (Class A Stock) (XP). Option delistings effective January 23rd include McDermott International Inc (MDR) and Teekay Offshore Partners LP (Units) (TOO).